Literature DB >> 10360402

Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations.

S G Brodie1, H Kitoh, R S Lachman, L M Nolasco, P B Mekikian, W R Wilcox.   

Abstract

The platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of short-limb dwarfing conditions. The most common form of PLSD is thanatophoric dysplasia (TD), which has been divided into two types (TD1 and TD2). Three other types of PLSD, or TD variants (San Diego, Torrance, and Luton), have been distinguished from TD. The most notable difference between TD and the variants is the presence of large rough endoplasmic reticulum (rER) inclusion bodies within chondrocytes of the variants. We examined 22 cases of TD variants for the presence of missense mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. All 17 cases of the San Diego type (PLSD-SD) were heterozygous for the same FGFR3 mutations found in TD1. No mutations were identified in the Torrance and Luton types. Large inclusion bodies were found in all 14 cases of PLSD-SD. Similar inclusion bodies were present in two of 72 TD1 cases, but not in 39 controls. The material retained within the rER stained only with antibody to the FGFR3 protein. The radiographic and morphologic differences between TD and PLSD-SD may be a consequence of other genetic factors, perhaps in the processing of mutant FGFR3 molecules within the rER. The presence of rER inclusion bodies cannot reliably discriminate between closely related skeletal dysplasias.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360402

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  12 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 2.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

3.  FGF9 on the move.

Authors:  Douglas Spicer
Journal:  Nat Genet       Date:  2009-03       Impact factor: 38.330

Review 4.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

Review 5.  Genetic analysis of skeletal dysplasia: recent advances and perspectives in the post-genome-sequence era.

Authors:  Shiro Ikegawa
Journal:  J Hum Genet       Date:  2006-05-03       Impact factor: 3.172

Review 6.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

Review 7.  Survival to adulthood and dominant inheritance of platyspondylic skeletal dysplasia, Torrance-Luton type.

Authors:  Luitgard Neumann; Jürgen Kunze; Markus Uhl; Brigitte Stöver; Bernhard Zabel; Jürgen Spranger
Journal:  Pediatr Radiol       Date:  2003-09-05

8.  FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry.

Authors:  Yuan Xue; Angela Sun; P Betty Mekikian; Jorge Martin; David L Rimoin; Ralph S Lachman; William R Wilcox
Journal:  Mol Genet Genomic Med       Date:  2014-08-05       Impact factor: 2.183

Review 9.  Fibroblast growth factor signaling in skeletal development and disease.

Authors:  David M Ornitz; Pierre J Marie
Journal:  Genes Dev       Date:  2015-07-15       Impact factor: 11.361

Review 10.  Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.

Authors:  Teresa Helsten; Maria Schwaederle; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.